Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4245)	3/6/2000 5:55:00 PM
From: PaulW	Read Replies (2) of 10280

Peter: Any thoughts where this fits in the scheme of things: Monday March 6, 8:45 am Eastern Time Company Press Release SOURCE: Merck & Co., Inc. Singulair(R) 4 Mg Tablet is Approved by FDA to Help Control Asthma In Children Two to Five Years of Age New Strength of Popular Asthma Medicine is the First Once-a-Day Chewable Pill For Children With Asthma as Young as Two <snip> But today the parents of children ages two to five years with asthma have a new treatment option that is a once-a-day medicine and is not a steroid. The U.S. Food and Drug Administration (FDA) has approved Singulair© (montelukast sodium) 4 mg tablets for the prevention and chronic treatment of asthma in children aged two to five. Currently, few options exist to treat asthma in this age group. Singulair is the first asthma controller therapy in more than 15 years indicated for children as young as two. Singulair 4 mg comes in a convenient cherry-flavored chewable tablet. <snip> biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next